Clinical Trial Update: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin [Phase 2]

View source ↗

Summary

Extension Phase 2 study evaluating long-term safety, tolerability, and body-weight effects of combining pramlintide with metreleptin in obesity has completed; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• MYALEPT (METRELEPTIN)
• Symlin (pramlintide)

Snippet

Sponsor: AstraZeneca | Conditions: Obesity | Phase 2 | Status: COMPLETED | Results posted: 2013-12-05